Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22787186 | 0.90 | KMT2A (0.38) | KMT2ALMNAPOLBMAPK1ALDH1A1 | |
| SCHEMBL22773695 | 0.90 | KMT2A (0.38) | KMT2ALMNAPOLBMAPK1ALDH1A1 | |
| SCHEMBL22773697 | 0.90 | KMT2A (0.38) | KMT2ALMNAPOLBMAPK1ALDH1A1 | |
| SCHEMBL24699977 | 0.82 | LMNA (0.35) | KMT2ALMNAPOLBMAPK1ALDH1A1 | |
| SCHEMBL22787185 | 0.76 | KMT2A (0.41) | KMT2ALMNAPOLBMAPK1ALDH1A1 | |
| SCHEMBL29526363 | 0.76 | KMT2A (0.41) | KMT2ALMNAPOLBMAPK1ALDH1A1 | |
| SCHEMBL22773527 | 0.76 | KMT2A (0.41) | KMT2ALMNAPOLBMAPK1ALDH1A1 | |
| SCHEMBL22773528 | 0.76 | KMT2A (0.41) | KMT2ALMNAPOLBMAPK1ALDH1A1 | |
| SCHEMBL14616550 | 0.75 | MAPT (0.53) | KMT2ALMNAPOLBMAPK1ALDH1A1 | |
| SCHEMBL22787194 | 0.73 | HSD17B10 (0.45) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267281-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267281-A1 | UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | AADAC, ACSL3, ACSL1 | KMT2A 2302/4885LMNA 845/4885POLB 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.